[Federal Register Volume 67, Number 128 (Wednesday, July 3, 2002)]
[Notices]
[Pages 44610-44611]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-16692]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Request for Nominations for Voting Members on Public Advisory 
Committees

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

    The Food and Drug Administration (FDA) is requesting nominations 
for voting members to serve on the Allergenic Products Advisory 
Committee, Biological Response Modifiers Advisory Committee, Blood 
Products Advisory Committee, Transmissible Spongiform Encephalopathies 
Advisory Committee, and the Vaccines and Related Biological Products 
Advisory Committee in the Center for Biologics Evaluation and Research 
(CBER). Nominations will be accepted for vacancies that will or may 
occur through December 31, 2003.
    FDA has a special interest in ensuring that women, minority groups, 
and individuals with disabilities are adequately represented on 
advisory committees and, therefore, encourages nominations of qualified 
candidates from these groups.

DATES:  Because scheduled vacancies occur on various dates throughout 
each year, no cutoff date is established for the receipt of 
nominations. However, when possible, nominations should be received at 
least 6 months before the date of scheduled vacancies for each year, as 
indicated in this notice.

ADDRESSES:  All nominations and curricula vitae should be sent to the 
appropriate contact person in the FOR FURTHER INFORMATION CONTACT 
section of this document.

FOR FURTHER INFORMATION CONTACT:
    Regarding nominations except for consumer representatives: Jane 
Brown, Scientific Advisors and Consultants Staff, Center for Biologics 
Evaluation and Research (HFM-71), Food and Drug Administration, 1401 
Rockville Pike, Rockville, MD 20852-1448, 301-827-0314.
    Regarding nominations for consumer representatives: Linda Sherman, 
Advisory Committee Oversight and Management Staff (HF-4), Food and Drug 
Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations of voting 
members with appropriate expertise for vacancies listed as follows:
    1. Allergenic Products Advisory Committee: Three vacancies 
occurring August 31, 2003; immunology, pediatrics, internal medicine, 
biochemistry, statistics, consumer interest, and related scientific 
fields.
    2. Blood Products Advisory Committee: One vacancy occurring 
September 30, 2002; and six vacancies occurring September 30, 2003; 
clinical and administrative medicine, hematology, immunology, blood 
banking, surgery, internal medicine, biochemistry, engineering, 
statistics, biological and physical sciences, and other related 
scientific fields.
    3. Transmissible Spongiform Encephalopathies Advisory Committee: 
Five vacancies occurring January 31, 2003; clinical administrative 
medicine, hematology, virology, neurology, infectious diseases, 
immunology, blood banking, surgery, internal medicine, biochemistry, 
biostatistics, epidemiology, biological and physical sciences, 
sociology/ethics, and other related professions.
    4. Vaccines and Related Biological Products Advisory Committee: 
Five vacancies occurring January 31, 2003; immunology, molecular 
biology, recombinant deoxyribonucleic acid (rDNA), virology, 
bacteriology, epidemiology, biostatistics, allergy, preventive 
medicine, infectious diseases, pediatrics, microbiology, biochemistry, 
and consumer interest.

Functions

1. Allergenic Products Advisory Committee

    Reviews and evaluates available data concerning the safety, 
effectiveness, and adequacy of labeling of marketed and investigational 
allergenic biological products or materials that are administered to 
humans for the diagnosis, prevention, or treatment of allergies and 
allergic diseases.

2. Blood Products Advisory Committee

    Reviews and evaluates available data concerning the safety, 
effectiveness, and appropriate use of blood and products derived from 
blood and serum or biotechnology which are intended for use in the 
diagnosis, prevention, or treatment of human diseases.

3. Transmissible Spongiform Encephalopathies Advisory Committee

    Reviews and evaluates available scientific data concerning the 
safety of products which may be at risk for transmission of spongiform 
encephalopathies having an impact on the public health.

4. Vaccines and Related Biological Products Advisory Committee

    Reviews and evaluates data concerning the safety, effectiveness, 
and appropriate use of vaccines and related biological products which 
are intended for use in the prevention, treatment, or diagnosis of 
human diseases.

Qualifications

    Persons nominated for membership on the committees shall have 
adequately diversified experience appropriate to the work of the 
committee in such fields as clinical and administrative medicine, 
engineering, biological and physical sciences, statistics, and other 
related professions. The nature of specialized training and experience 
necessary to qualify the nominee as an expert suitable for appointment 
may include experience in medical practice, teaching, and/or research 
relevant to the

[[Page 44611]]

field of activity of the committee. The particular needs at this time 
for each committee are shown in the first paragraph of the 
SUPPLEMENTARY INFORMATION section of this document. The term of office 
is up to 4 years, depending on the appointment date.

Nomination Procedures

    Any interested person may nominate one or more qualified persons 
for membership on one or more of the advisory committees. Self-
nominations are also accepted. Nominations shall include the name of 
the committee, a complete curriculum vitae of each nominee, current 
business address and telephone number, and shall state that the nominee 
is aware of the nomination, is willing to serve as a member (name of 
committee(s) must be specified), and appears to have no conflict of 
interest that would preclude membership. FDA will ask the potential 
candidates to provide detailed information concerning such matters as 
financial holdings, employment, and research grants and/or contracts to 
permit evaluation of possible sources of conflict of interest.

Consumer Representatives

    Any interested person may nominate one or more qualified persons 
for membership on one or more of the advisory committees to represent 
consumer interests. Self-nominations are also accepted. To be eligible 
for selection, the applicant's experience and/or education will be 
evaluated against Federal civil service criteria for the position to 
which the person will be appointed.
    Selection of members representing consumer interests is conducted 
through procedures that include use of a group of consumer 
organizations that has the responsibility for recommending candidates 
for the agency's selection. Candidates should possess appropriate 
qualifications to understand and contribute to the committee's work.
    Nominations shall include a complete curriculum vita of each 
nominee, current address and telephone numbers, and shall state that 
the nominee is aware of the nomination, is willing to serve as a 
member, and appears to have no conflict of interest that would preclude 
membership. FDA will ask the potential candidates to provide detailed 
information concerning such matters as financial holdings, employment, 
and research grants and/or contracts to permit evaluation of possible 
sources of conflict of interest. The nomination should state whether 
the nominee is interested only in a particular advisory committee or in 
any advisory committee. The term of office is up to 4 years, depending 
on the appointment date.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.

    Dated: June 24, 2002.
William K. Hubbard,
Senior Associate Commissioner for Policy, Planning, and Legislation.
[FR Doc. 02-16692 Filed 7-2-02; 8:45 am]
BILLING CODE 4160-01-S